JP2023536068A - クレノラニブの結晶形態およびそれを用いる方法 - Google Patents

クレノラニブの結晶形態およびそれを用いる方法 Download PDF

Info

Publication number
JP2023536068A
JP2023536068A JP2023503219A JP2023503219A JP2023536068A JP 2023536068 A JP2023536068 A JP 2023536068A JP 2023503219 A JP2023503219 A JP 2023503219A JP 2023503219 A JP2023503219 A JP 2023503219A JP 2023536068 A JP2023536068 A JP 2023536068A
Authority
JP
Japan
Prior art keywords
crystalline form
cancer
peaks
powder
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023503219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536068A5 (enExample
Inventor
ジャイン，ビナイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arog Pharmaceuticals LLC
Original Assignee
Arog Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arog Pharmaceuticals LLC filed Critical Arog Pharmaceuticals LLC
Publication of JP2023536068A publication Critical patent/JP2023536068A/ja
Publication of JP2023536068A5 publication Critical patent/JP2023536068A5/ja
Priority to JP2026043122A priority Critical patent/JP2026116949A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023503219A 2020-07-20 2021-05-21 クレノラニブの結晶形態およびそれを用いる方法 Pending JP2023536068A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026043122A JP2026116949A (ja) 2020-07-20 2026-03-17 クレノラニブの結晶形態およびそれを用いる方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063053921P 2020-07-20 2020-07-20
US63/053,921 2020-07-20
PCT/US2021/033618 WO2022019998A1 (en) 2020-07-20 2021-05-21 Crystal forms of crenolanib and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026043122A Division JP2026116949A (ja) 2020-07-20 2026-03-17 クレノラニブの結晶形態およびそれを用いる方法

Publications (2)

Publication Number Publication Date
JP2023536068A true JP2023536068A (ja) 2023-08-23
JP2023536068A5 JP2023536068A5 (enExample) 2024-01-24

Family

ID=79291977

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023503219A Pending JP2023536068A (ja) 2020-07-20 2021-05-21 クレノラニブの結晶形態およびそれを用いる方法
JP2026043122A Pending JP2026116949A (ja) 2020-07-20 2026-03-17 クレノラニブの結晶形態およびそれを用いる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026043122A Pending JP2026116949A (ja) 2020-07-20 2026-03-17 クレノラニブの結晶形態およびそれを用いる方法

Country Status (7)

Country Link
US (3) US11713310B2 (enExample)
EP (1) EP4181923A4 (enExample)
JP (2) JP2023536068A (enExample)
CN (1) CN113956245A (enExample)
CA (1) CA3186319A1 (enExample)
TW (2) TW202613103A (enExample)
WO (1) WO2022019998A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501309A (ja) * 2002-08-28 2006-01-12 ファイザー・プロダクツ・インク 抗増殖剤として有効な新規ベンゾイミダゾール誘導体
JP2007516168A (ja) * 2003-06-24 2007-06-21 ファイザー・プロダクツ・インク １−［２−（ベンゾイミダゾル−１−イル）キノリン−８−イル］−ピペリジン−４−イルアミン誘導体の製造方法
JP2014065696A (ja) * 2012-09-26 2014-04-17 Arog Pharmaceuticals Llc 変異型ｃ−ｋｉｔの阻害方法
JP2014097929A (ja) * 2012-09-21 2014-05-29 Arog Pharmaceuticals Llc 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
JP2016508148A (ja) * 2013-01-07 2016-03-17 エーアールオージー ファーマスーティカルズ，インクＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ）
JP2019532011A (ja) * 2016-11-02 2019-11-07 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
WO2020123991A1 (en) * 2018-12-13 2020-06-18 Arog Pharmaceuticals, Inc. Crenolanib combination therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
US6960590B2 (en) 2000-10-17 2005-11-01 Merck & Co. Inc. Orally active salts with tyrosine kinase activity
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
PT1441737E (pt) 2001-10-30 2006-12-29 Dana Farber Cancer Inst Inc Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3
DE60205776T2 (de) 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
SG148864A1 (en) 2002-11-13 2009-01-29 Chiron Corp Methods of treating cancer and related methods
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
US7226919B2 (en) 2002-12-18 2007-06-05 Vertex Pharmaceuticals Inc. Compositions useful as inhibitors of protein kinases
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
CN105294719B (zh) * 2015-11-18 2017-12-22 乳源瑶族自治县大众药品贸易有限公司 一种氨基喹唑啉类衍生物的二对甲苯磺酸盐及其晶型
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006501309A (ja) * 2002-08-28 2006-01-12 ファイザー・プロダクツ・インク 抗増殖剤として有効な新規ベンゾイミダゾール誘導体
JP2007516168A (ja) * 2003-06-24 2007-06-21 ファイザー・プロダクツ・インク １−［２−（ベンゾイミダゾル−１−イル）キノリン−８−イル］−ピペリジン−４−イルアミン誘導体の製造方法
JP2014097929A (ja) * 2012-09-21 2014-05-29 Arog Pharmaceuticals Llc 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
JP2014065696A (ja) * 2012-09-26 2014-04-17 Arog Pharmaceuticals Llc 変異型ｃ−ｋｉｔの阻害方法
JP2016508148A (ja) * 2013-01-07 2016-03-17 エーアールオージー ファーマスーティカルズ，インクＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 変異ｆｌｔ３増殖性障害の治療剤クレノラニブ（ｃｒｅｎｏｌａｎｉｂ）
JP2019532011A (ja) * 2016-11-02 2019-11-07 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｆｌｔ３突然変異増殖性疾患および関連する突然変異を治療するためのクレノラニブ
WO2020123991A1 (en) * 2018-12-13 2020-06-18 Arog Pharmaceuticals, Inc. Crenolanib combination therapy

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
""新医薬品の規格及び試験方法の設定について"", 医薬審発第568号, JPN6010021254, 1 May 2001 (2001-05-01), ISSN: 0005732930 *
BERGE，S. M., ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN5004004439, 1977, US, pages 1 - 19, ISSN: 0005732928 *
STEPHEN BYRN ET AL.: ""Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations"", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, JPN5013009960, 1995, pages 945 - 954, ISSN: 0005558335 *
大嶋寛: ""結晶多形・擬多形の析出挙動と制御"", PHARM STAGE, vol. 6, no. 10, JPN6011001457, 15 January 2007 (2007-01-15), pages 48 - 53, ISSN: 0005732931 *
山野光久: "医薬品のプロセス研究における結晶多形現象への取り組み", 有機合成化学協会誌, vol. 65, no. 9, JPN6010003277, 1 September 2007 (2007-09-01), ISSN: 0005732933 *
川口洋子，外２名: ""医薬品と結晶多形"", 生活工学研究, vol. 第４巻第２号, JPN6014015069, 2002, pages 310 - 317, ISSN: 0005732929 *
浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0005732935 *
社団法人日本化学会編, 第４版実験化学講座１基本操作Ｉ, vol. 第１８４−１８９頁, JPN7008003682, 5 April 1996 (1996-04-05), ISSN: 0005732936 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005558333 *

Also Published As

Publication number Publication date
WO2022019998A1 (en) 2022-01-27
US11713310B2 (en) 2023-08-01
TWI905226B (zh) 2025-11-21
US20230339918A1 (en) 2023-10-26
JP2026116949A (ja) 2026-07-14
US20220017500A1 (en) 2022-01-20
US20260159506A1 (en) 2026-06-11
US12486256B2 (en) 2025-12-02
CA3186319A1 (en) 2022-01-27
EP4181923A4 (en) 2024-08-07
CN113956245A (zh) 2022-01-21
EP4181923A1 (en) 2023-05-24
TW202216696A (zh) 2022-05-01
TW202613103A (zh) 2026-04-01

Similar Documents

Publication Publication Date Title
CN101578283B (zh) 噻唑烷二酮化合物的晶形及其制造方法
RU2652121C2 (ru) Многокомпонентная кристаллическая система, содержащая нилотиниб и выбранные сокристаллообразователи
RU2672563C1 (ru) Кристаллы 3,5-дизамещенного бензолалкинильного соединения
JP7818666B2 (ja) ピリジノイルピペリジン５－ｈｔ１ｆアゴニストに関する組成物および方法
JP2023175689A (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
JP2003530321A (ja) Ｎ−［４−［２−（２−アミノ−４，７−ジヒドロ−４−オキソ−３Ｈ−ピロロ［２，３−ｄ］ピリミジン−５−イル）エチル］ベンゾイル］−Ｌ−グルタミン酸の新規結晶形およびその製造方法
JP5758399B2 (ja) 化合物、その一定の新形態、その医薬組成物ならびに製剤化および使用の方法
WO2024248083A1 (ja) キノリン置換化合物の結晶
JPS604188B2 (ja) ２−〔４−（２−フロイル）ピペラジン−１−イル〕−４−アミノ−６，７−ジメトキシキナゾリン塩酸塩の新規な結晶形
JP6185490B2 (ja) ３−（４−ニトロ−１−オキソイソインドリン−２−イル）ピペリジン−２，６−ジオンの固体形態
US12486256B2 (en) Crystal forms of crenolanib and methods of use thereof
EP3023421A1 (en) Crystalline forms of afatinib dimaleate
JP2024542840A (ja) Ｆｇｆｒ阻害剤の固体状形態
JPWO2012147832A1 (ja) フェニルピロール誘導体の結晶
TW201008935A (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
CN105753869B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
WO2022256550A1 (en) Crystalline forms of an adenosine a2b receptor antagonist
EA006857B1 (ru) КРИСТАЛЛИЧЕСКАЯ ФОРМА ПРОИЗВОДНОГО РИБОФУРАНОЗИЛУРОНАМИДА, АГОНИСТ РЕЦЕПТОРА A2a АДЕНОЗИНА ЧЕЛОВЕКА
CN105732642B (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
TW201125861A (en) CDC7 inhibitor salts
RU2336269C2 (ru) Кристаллическое индолсульфонамидное соединение и способ его получения
WO2026095022A1 (ja) キノリン置換化合物の結晶
WO2022144042A1 (zh) Tas-116的晶型及其制备方法、药物组合物和用途
CN113929630B (zh) 一种吉非替尼药物共晶体
JP2025541840A (ja) 固体分散体、その製造方法と使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250325

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250925

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251118